FREMONT, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, continues its commitment to advancing the cell analysis market by actively participating in key industry gatherings worldwide. The company's Full Spectrum Profiling™ (FSP™) technology, designed for streamlining workflows, expediting discoveries, and enhancing efficiency, will be prominently featured at both CYTO 2024 and AAI’s IMMUNOLOGY2024.
The company's distinctive approach to spectral flow cytometry is renowned for its profound influence on advancing the understanding of cell biology, immunology, immunotherapy, oncology and targeted therapeutic methodologies.
IMMUNOLOGY2024
May 3, 2024 – May 7, 2024
Chicago, IL
Booth #755
The American Association of Immunologists’ (AAI) 107th annual meeting will bring leading researchers together to explore the latest developments in the field of immunology. Cytek will be on hand to showcase its complete cell analysis solutions that enable scientists to advance their research, gain deeper insights, and fast-track discovery. The company’s comprehensive, integrated suite of solutions includes the Cytek portfolio of instruments, reagents, Cytek® Cloud, software and services.
Also at IMMUNOLOGY2024, Eleanor Kincaid, Ph.D., field applications manager, eastern U.S. for Cytek Biosciences, will host an exhibitor workshop geared toward researchers seeking a deeper understanding of the complexities of the human immune system. Titled “High Resolution In-Depth Characterization of the Human Memory T Cell Compartment Using Full Spectrum Profiling Technology,” this workshop will take place on Saturday, May 4, from 2:15 p.m. – 3:00 p.m.
CYTO 2024
May 4, 2024 – May 8, 2024
Edinburgh, Scotland
Booths #17 and 98
A premier international conference, CYTO 2024 is where pioneers in flow cytometry converge to share insights, discoveries, and advancements in cellular analysis. CYTO serves as a nexus for researchers and industry leaders to explore the latest technologies, methodologies, and applications shaping the field. At CYTO, Cytek will showcase its FSP technology, focusing on its potential to accelerate scientific discovery. Cytek continues to add product enhancements to its spectral analyzers, increasing throughput, enabling walk-away automation, and adding chilling to the automated sample loader. These enhancements aim to improve lab efficiency and productivity.
Also at the show, Cytek scientists will conduct two tutorial sessions. Cytek’s global scientific director, Diana L. Bonilla Escobar, Ph.D., will lead a session titled, “The Balancing Act Between Number of Colors and Data Quality: Lessons Learned from Human Memory T Cells,” on Monday, May 6, from 12:15 p.m. – 1:15 p.m. Additionally, Maria C. Jaimes, M.D., vice president of scientific commercialization for Cytek, will conduct a session titled, “Are All Spectral Cytometers Equal? An Analysis from The Perspective of Multicolor Assay Performance,” on Tuesday, May 7, from 12:15 p.m. – 1:15 p.m.
"At Cytek, we’re focused on delivering innovative, powerful solutions that enable scientists to rapidly and efficiently obtain deep insights and understanding of biological systems,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “Our continued participation in the scientific community’s most important events underscores our commitment to providing researchers with the tools they need to drive groundbreaking discoveries."
For more information, please visit www.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS; the flow cytometer and imaging products under the Amnis® and Guava® brands; the Cytek Orion™ reagent cocktail preparation system, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding Cytek’s business and product plans and strategies. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to Cytek’s ability to manage the growth and complexity of its organization; Cytek’s ability to manage relationships with key customers and suppliers; Cytek’s ability to retain key employees; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; global economic and market conditions; competition; and Cytek’s dependence on certain sole and single source suppliers. You should refer to the section entitled “Risk Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC and other filings Cytek Biosciences makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
